Brukinsa (zanubrutinib) — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of relapsed or refractory FL (ICD-10 C82)
• use in combination with obinutuzumab (Gazyva)
• received at least two prior lines of systemic therapy